ULCERATIVE COLITIS MARKET ANALYSIS

Market News

Key Developments

1. Key players in the market are focused on various growth strategies such research and development of novel products, in order to enhance their product portfolio. For instance, in October 2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness and safety in the treatment of ulcerative colitis in a 24-month open label extension study.
2. Major companies in the market are involved in various business strategies such research and development of novel products, in order to enhance their product portfolio. For instance, in March 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Phase III data UNFI study data for Stelara, a subcutaneous maintenance therapy, which showed positive results as maintenance therapy in adults suffering from moderate to severe ulcerative colitis.
3. Major companies in the market are involved in various growth strategies such research and development of novel products, in order to enhance their market presence. For instance, in August 2019, Takeda Pharmaceutical Company Limited, submitted new drug application (NDA) to Ministry of Health, Labour and Welfare in Japan for subcutaneous formulation of vedolizumab, which will be used as maintenance therapy in adults with moderate to severe ulcerative colitis.